Ultrasound-guided Peripheral Intravenous Catheter Placement in an Oncologic Emergency Department - a Prospective, Randomized Controlled Trial of Catheter Lengths
Launched by M.D. ANDERSON CANCER CENTER · Jan 12, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how the length of a special tube called a catheter affects its success when placed in patients who may have difficulty getting an intravenous (IV) line. The study is focusing on patients in an emergency department for cancer-related issues. By using ultrasound to help place the catheter, researchers want to determine whether different lengths of these tubes can lead to better or worse outcomes for patients needing IV access.
To be eligible for this trial, participants must be over 18 years old and have been identified as needing a catheter due to difficult IV access. They should expect to stay in the hospital for more than 48 hours. Those who cannot give consent, are pregnant, or do not speak English are not included. If you join the study, you’ll be randomly assigned to receive a catheter of a certain length, and the team will monitor how well it works for you. This research aims to improve care for patients facing challenges with IV access.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age \> 18 years old.
- • 2. Provision of signed and dated informed consent form.
- • 3. Predetermined to have difficult IV access necessitating USIV placement
- • 4. Expected admission to hospital with anticipated stay \> 48 hours (per discussion with treating physician).
- Exclusion Criteria:
- • 1. Expected/anticipated discharge disposition from the ACCC (per discussion with treating physician).
- • 2. Inability to give informed consent.
- • 3. Pregnant women.
- • 4. Non-English speaking participants.
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Jonathan Rowland, MD
Principal Investigator
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported